Shots:
- The collaboration will evaluate Fusion’s FPI-1434 + Merck’s Keytruda in patients with solid tumors expressing IGF-1R. Fusion will sponsor the study and Merck will supply Keytruda
- The companies plan to initiate a P-I/II trial to evaluate the safety, tolerability, and PK of combination therapy and is expected in ~6 to 9 mos. upon achieving the RP2D in the ongoing P-I study of FPI-1434 monothx
- The preclinical data demonstrated promising activity with FPI-1434 and immuno-oncology agents. The collaboration aims to expand the radiopharmaceutical therapies, including advancing in earlier cancer therapy lines
Click here to read full press release/ article | Ref: PRNewswire | Image: Merck
The post Merck and Fusion Pharmaceuticals Enter into a Clinical Collaboration for FPI-1434 + Keytruda (pembrolizumab) to Treat Solid Tumors Expressing IGF-1R first appeared on PharmaShots.
